GlassScriptPhysician profile
Joseph G Birnbaum
NPI 1669417788
$16,741.17
in general payments reported to CMS, 2019-2025
39 companies · $3,086 in 2025
The $3,086 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,232 · 2020: $2,115 · 2021: $2,745 · 2022: $2,412 · 2023: $1,916 · 2024: $2,235 · 2025: $3,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,149 · Education: $87.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,149.12 |
| Education | $87.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,408.61 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,854.13 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amneal Pharmaceuticals LLC | $1,545.05 | 2019-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $1,458.35 | 2019-2024 | Farxiga, Lokelma |
| Abbvie INC. | $1,347.11 | 2019-2025 | Ubrelvy |
| Corcept Therapeutics | $1,213.33 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $927.80 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $835.35 | 2019-2025 | |
| Dexcom, INC. | $431.28 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $419.88 | 2021-2025 | |
| Abbott Laboratories | $373.46 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $311.57 | 2019-2025 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $310.20 | 2019-2022 | |
| Amgen INC. | $299.47 | 2019-2025 | Repatha, Tepezza |
| Ibsa Pharma INC. | $280.80 | 2019-2025 | Tirosint, Licart, Flector |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $264.60 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amarin Pharma, INC. | $253.27 | 2020-2022 | |
| Mannkind Corporation | $211.06 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $191.42 | 2019-2020 | |
| Antares Pharma, INC. | $127.34 | 2019-2025 | Xyosted |
| Esperion Therapeutics, INC. | $116.67 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $99.06 | 2021-2024 | |
| Arbor Pharmaceuticals, INC. | $73.01 | 2019-2022 | |
| Lifescan, INC. | $58.12 | 2020-2022 | |
| Tandem Diabetes Care, INC. | $42.95 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $40.07 | 2024-2025 | Cequr Simplicity |
| Glaxosmithkline, LLC. | $37.47 | 2025 | Shingrix, Arexvy |
| Amryt Pharma Holdings LTD | $34.89 | 2023 | Myalept |
| Boston Scientific Corporation | $21.86 | 2023 | Watchman Flx |
| Beta Bionics, INC. | $18.33 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascendis Pharma Endocrinology INC | $17.98 | 2025 | Yorvipath |
| Astellas Pharma US INC | $16.45 | 2024 | Veozah |
| Recordati_rare_diseases_inc. | $16.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.97 | 2019 | |
| Ionis Pharmaceuticals, INC. | $14.93 | 2025 | Tryngolza |
| Rhythm Pharmaceuticals, INC. | $14.54 | 2025 | Imcivree |
| Intuity Medical INC | $14.31 | 2022 | |
| Horizon Therapeutics Plc | $12.85 | 2022 | |
| Acerus Pharmaceuticals Corporation | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Birnbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.